Theranostic Applications of Lutetium-177 in Radionuclide Therapy.

Abstract

Lutetium-177 has been widely discussed as a radioisotope of choice for targeted radionuclide therapy. The simultaneous emission of imageable gamma photons [208 keV (11%) and 113 keV (6.4%)] along with particulate β(-) emission [β(max) = 497 keV] makes it a theranostically desirable radioisotope. In the present article, the possibility of using two 177Lu-based agents viz. 177Lu-EDTMP and 177Lu-DOTATATE for theranostic applications in metastatic bone pain palliation (MBPP) and peptide receptor radionuclide therapy (PRRT), have been explored. In the case of 177Lu-EDTMP, the whole-body images obtained are compared with those recorded using 99mTc-MDP in the same patient. On the other hand, pre-therapy images acquired with 177Lu-DOTA-TATE are compared with similar images obtained with standard agents, such as 99mTc-HYNIC-TOC (SPECT) and 68Ga-DOTA-TOC (PET) in the same patient. The advantage of the long physical half-life (T1/2) of 177Lu has been utilized in mapping the pharmacokinetics of two additional agents, 177Lu-labeled hydroxyapatite (HA) in radiation synovectomy of knee joints and 177Lu-HA for therapy of hepatocellular carcinoma. Results of these multiple studies conclusively document the potential of 177Lu as a theranostic radioisotope.

• Authors: Tapas Das, Sharmila Banerjee
• Journal: Current radiopharmaceuticals (Curr Radiopharm) Vol. 9 Issue 1 Pg. 94-101 ( 2016) ISSN: 1874-4729 [Electronic] United Arab Emirates
• PMID: 25771364 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Organometallic Compounds
• Organophosphorus Compounds
• Radioisotopes
• Radiopharmaceuticals
• Receptors, Peptide
• lutetium ethylenediaminetetramethylene phosphonic acid
• Durapatite
• lutetium Lu 177 dotatate
• Octreotide

Topics

• Bone Neoplasms (radiotherapy, secondary)
• Durapatite (administration & dosage)
• Half-Life
• Humans
• Octreotide (administration & dosage, analogs & derivatives, pharmacokinetics)
• Organometallic Compounds (administration & dosage, pharmacokinetics)
• Organophosphorus Compounds (administration & dosage, pharmacokinetics)
• Pain (etiology, radiotherapy)
• Radioisotopes (administration & dosage, pharmacokinetics)
• Radiopharmaceuticals (administration & dosage, pharmacokinetics)
• Receptors, Peptide (metabolism)
• Theranostic Nanomedicine (methods)